Elite Launch Architecture for Advanced Metabolic Therapies
We help biotechs de-risk U.S. launches for GLP-1, dual and triple agonists, and modern obesity therapies by aligning evidence, access, and field execution.
The boutique your board hires when the launch cannot fail
Upper Echelon Management is a principal-led launch and retention architecture firm for advanced metabolic and obesity innovators. We combine 70% commercial rigor with 30% clinical fluency -- the exact blend that makes CCOs, payers, and physicians trust that your asset is clinically inevitable, not optional.
Unlike global strategy houses that hand off to junior teams, or contract organizations that sell volume, we stay in the room from day one through month twelve. Every engagement is led by senior operators who have sold and led teams on foundational diabetes and obesity brands across top-50 pharma and biotech companies.
EU & Japanese Mid-Cap Biotechs
Bringing their first advanced metabolic or obesity asset to the U.S. market with thin or zero commercial footprint.
U.S. Biotechs with Stalling Launches
In-market or near-launch GLP-1, dual/triple agonists, or obesity drugs facing early discontinuation and payer friction.
Specialty Biopharma Innovators
Companies in oncology support, rare disease, CNS, and other complex categories needing principal-level launch strategy.
Five pillars of launch certainty
Deep expertise where persistence determines value
Cardio-Metabolic
GLP-1, duals, triples, and related CV/renal launches
Obesity & Weight
Next-gen obesity agents and legacy weight-loss therapies
US Market Entry
EU/Japanese biotechs entering the U.S. market
Specialty Biopharma
Oncology support, rare disease, CNS, and complex launches
Selected engagement outcomes
National Field Team Expansion
Mid-cap biotech needed to scale from 25 to 60+ reps for a complex metabolic launch, with full clinical readiness from day one.
Designed squad architecture, ran clinical stress tests on every hire, and achieved top-quartile launch performance in priority territories.
GLP-1 Persistence Program
Early discontinuation rates eroding lifetime value. Standard patient support programs failing to address titration and side-effect drop-off.
Built a Retention Engine integrating nurse liaison, HCP coaching, and loyalty constructs that reduced early discontinuation in pilot populations.
Foreign Biotech US Gateway
EU-based mid-cap with zero US commercial footprint needed a complete launch infrastructure for their first metabolic asset.
Served as de facto Head of US Launch -- built the commercial architecture, hired the initial field team, and aligned KOL and payer narratives.
Obesity Launch Hiring
Generalist recruiters produced three rounds of weak candidates. Launch timeline threatened.
Used clinical stress testing and network-level vetting to deliver a curated slate in 4 weeks. Zero first-year turnover among UEM-vetted hires.
Engagement footprint
We advise GLP-1 originators, CDMOs, licensees, and platform companies across four continents. All engagements are conducted under NDA; descriptions are anonymized.
Europe & UK
Clinical-stage biotech developing GLP-1/GIP dual agonist for obesity with significant private backing
Asia-origin biotech with EU-partnered triple GLP-1/GIP/glucagon agonist licensed to a top-5 global pharma
South Korea
Multiple mid-cap pharma and biotech firms developing once-weekly injectable and oral GLP-1 obesity candidates through Phase 2-3
Major contract manufacturers scaling GLP-1 production capacity with multi-year, billion-dollar supply agreements
Metabolic-disease startups with multinational pharma partnerships on next-gen oral and long-acting formulations
China
Regional biotech with GLP-1 injection licensed to a top-5 global pharma in a deal valued in the hundreds of millions
Mid-size pharma partnered with a top-5 global company on investigational GLP-1 program with milestone potential exceeding $1B
India
Leading API and contract manufacturing supplier scaling GLP-1 peptide production, with metabolic revenue projected to approach $1B within the decade
From diagnostic to launch certainty
Stress Test
30-minute diagnostic conversation to identify where your launch is most exposed.
Retention Audit
Quantify leakage, map the patient journey, and deliver a prioritized Retention Blueprint.
Architecture Build
Design launch, retention, and talent architecture. Stand up field model and KOL strategy.
Govern & Optimize
Ongoing governance, war-room facilitation, and real-time optimization of launch KPIs.
What our clients say
Echelon stepped into our GLP-1 launch when we were already behind and helped us re-architect the entire commercial plan without derailing timelines. Within two quarters, early discontinuation improved in our pilot regions and our board finally had a defensible story on persistence and payer value.
James D.
COO -- SF-based biotech
As a first-time entrant into the U.S. market, we needed someone who had actually built and led field teams in complex metabolic categories. Echelon gave us a practical launch blueprint, helped us structure our US entry model, and coached our leadership through decisions that would have taken months on our own.
Karen M.
Chief Commercial Officer -- EU mid-cap entering US
We engaged Echelon to stress-test our cardio-metabolic launch and ended up relying on them far beyond the initial audit. They translated a messy mix of payer feedback, RWE, and field anecdotes into a clear access narrative and operational priorities that gave us real leverage in negotiations.
David L.
VP Market Access -- US specialty pharma
Echelon helped us bridge not just the science but the culture gap between our headquarters and the U.S. market. They were candid about trade-offs, decisive when we needed a recommendation, and respectful of our internal stakeholders. We would not attempt another U.S. launch without a partner like this.
Julia S.
Head of US Commercial -- Japan-based biopharma
Echelon's Talent Architecture work -- especially their interview stress tests and fit scoring -- completely changed how we hire and develop managers. The difference in day-one readiness of our new hires has been obvious, and our regional leaders now have a much clearer standard for what 'good' looks like.
Michael R.
SVP Sales & Marketing -- Metabolic-focused biotech
We brought in Echelon to run a launch and retention diagnostic on a portfolio we thought we understood. They surfaced operational gaps that had never shown up on our dashboards. Their recommendations were specific, prioritized, and realistic for our size. The engagement paid for itself quickly.
Elena G.
General Manager -- US affiliate of global pharma
Schedule your 30-minute Launch Stress Test
A focused diagnostic conversation with our senior leadership to identify where your advanced metabolic or obesity launch is most exposed -- and what to do about it.